Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe

Abstract Developments in “-omics” are creating a paradigm shift in laboratory medicine leading to personalized medicine. This allows the increase in diagnostics and therapeutics focused on individuals rather than populations. In order to investigate whether laboratory medicine is ready to play a key role in the integration of personalized medicine in routine health care and set the state-of-the-art knowledge about personalized medicine and laboratory medicine in Europe, a questionnaire was constructed under the auspices of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and the European Society of Pharmacogenomics and Personalised Therapy (ESPT). The answers of the participating laboratory medicine professionals indicate that they are aware that personalized medicine can represent a new and promising health model, and that laboratory medicine should play a key role in supporting the implementation of personalized medicine in the clinical setting. Participants think that the current organization of laboratory medicine needs additional/relevant implementations such as (i) new technological facilities in -omics; (ii) additional training for the current personnel focused on the new methodologies; (iii) incorporation in the laboratory of new competencies in data interpretation and counseling; and (iv) cooperation and collaboration among professionals of different disciplines to integrate information according to a personalized medicine approach.

[1]  Denis Horgan,et al.  An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe , 2014, Public Health Genomics.

[2]  Urs A Meyer,et al.  Omics and drug response. , 2013, Annual review of pharmacology and toxicology.

[3]  R. Sitnik,et al.  Personalized medicine and the clinical laboratory , 2014, Einstein.

[4]  G. Siest,et al.  The theory of reference values: an unfinished symphony , 2013, Clinical chemistry and laboratory medicine.

[5]  Xavier Bossuyt,et al.  Laboratory medicine: challenges and opportunities. , 2007, Clinical chemistry.

[6]  G. Siest,et al.  Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study. , 1998, Clinical chemistry.

[7]  A. Terzic,et al.  Policies to aid the adoption of personalized medicine , 2014, Nature Reviews Drug Discovery.

[8]  Challenges and opportunities for medical directors in pathology and laboratory medicine: standardization, integration, and innovation. , 2010, American journal of clinical pathology.

[9]  William B. Bean,et al.  Biochemical Individuality: The Basis for the Genetotrophic Concept. , 1957 .

[10]  G. Pravettoni,et al.  Personalised medicine: the cognitive side of patients. , 2014, European journal of internal medicine.

[11]  Yvan Devaux,et al.  miRNAs as biomarkers of myocardial infarction: a step forward towards personalized medicine? , 2014, Trends in molecular medicine.

[12]  G. Siest,et al.  Clinical necessity of partitioning of human plasma haptoglobin reference intervals by recently-discovered rs2000999. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[13]  Olga Golubnitschaja,et al.  Predictive, Preventive and Personalised Medicine as the hardcore of ‘Horizon 2020’: EPMA position paper , 2014, EPMA Journal.

[14]  Jason Y. Park,et al.  The future of laboratory medicine - a 2014 perspective. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[15]  H. Lemke,et al.  Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within ‘Horizon 2020’ , 2014, EPMA Journal.

[16]  B. Melichar The highs and lows of tumor biomarkers: lost illusions , 2015, Clinical chemistry and laboratory medicine.

[17]  Pae C. Wu,et al.  Personalized diagnostics and biosensors: a review of the biology and technology needed for personalized medicine , 2014, Critical reviews in biotechnology.

[18]  E. Diamandis,et al.  Whole genome sequencing as a diagnostic test: challenges and opportunities. , 2014, Clinical chemistry.

[19]  A. Brand,et al.  Working towards personalization in medicine: main obstacles to reaching this vision from today's perspective. , 2014, Personalized medicine.

[20]  Mario Plebani,et al.  Personalized (laboratory) medicine: a bridge to the future , 2013, Clinical chemistry and laboratory medicine.

[21]  S. Visvikis-Siest,et al.  Inter-individual variation of inflammatory markers of cardiovascular risks and diseases , 2005, Clinical chemistry and laboratory medicine.

[22]  T. Obara,et al.  Awareness regarding clinical application of pharmacogenetics among Japanese pharmacists , 2015, Pharmacogenomics and personalized medicine.

[23]  O. Gottesman,et al.  Implementation and utilization of genetic testing in personalized medicine , 2014, Pharmacogenomics and personalized medicine.

[24]  M. Piccart,et al.  Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  U. Dirnagl,et al.  Biomedical research: increasing value, reducing waste , 2014, The Lancet.